Aug 08, 2022 4:01 pm EDT Atara Biotherapeutics Announces Second Quarter 2022 Financial Results and Corporate Strategy Update
Aug 04, 2022 4:01 pm EDT Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 03, 2022 4:01 pm EDT Atara Biotherapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conference
Aug 01, 2022 4:01 pm EDT Atara Biotherapeutics to Announce Second Quarter 2022 Financial Results on Monday, August 8, 2022
Jul 12, 2022 4:30 pm EDT Atara Biotherapeutics Announces Completion of the ATA188 Phase 2 EMBOLD Study Interim Analysis in Patients with Progressive MS
Jul 06, 2022 4:01 pm EDT Atara Biotherapeutics to Announce Completion of ATA188 Phase 2 EMBOLD Study Interim Analysis on Tuesday, July 12, 2022
Jul 01, 2022 7:57 pm EDT Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 04, 2022 9:00 am EDT Atara Biotherapeutics Announces First Clinical Data from Ongoing Tab-cel® European Multicenter Expanded Access Program (EAP) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and Update on Tab-cel EMA Regulatory Progress
Jun 03, 2022 4:01 pm EDT Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)